Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

143.18
+2.471.76%
Post-market: 142.40-0.7800-0.54%19:30 EDT
Volume:1.65M
Turnover:235.71M
Market Cap:14.60B
PE:20.98
High:144.56
Open:141.41
Low:140.36
Close:140.71
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:1.03
T/O Rate:1.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:3.95
PE(LYR):30.66

Loading ...

Neurocrine is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 14

Neurocrine price target raised to $200 from $155 at Truist

TIPRANKS
·
Jul 13

Analysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX)

TIPRANKS
·
Jul 13

Wedbush Lifts Price Target on Neurocrine Biosciences to $185 From $176, Keeps Outperform Rating

MT Newswires Live
·
Jul 13

Krystal Biotech Stock And 2 Biotech Names With Pipeline Catalysts

Simply Wall St.
·
Jul 13

Neurocrine Biosciences (NBIX) Posts Strong Q1 Results, Is More Upside Still Left?

Simply Wall St.
·
Jul 11

Did Neurocrine’s (NBIX) CRENESSITY Push Into Infants Just Recast Its Rare-Disease Strategy?

Simply Wall St.
·
Jul 10

Neurocrine Chief Regulatory Officer Ingrid Delaet Disposes of 14,571 Common Shares Worth $2.6 Million

Reuters
·
Jul 10

Neurocrine Biosciences Schedules Q2 Earnings Conference Call and Webcast

Reuters
·
Jul 10

Ovid Therapeutics Names Kevin Norrett Chief Business Officer

Reuters
·
Jul 08

RBC Capital Adjusts Neurocrine Biosciences Price Target to $195 From $183, Maintains Outperform Rating

MT Newswires Live
·
Jul 07

Neurocrine Begins Phase 2 Trial of Crinecerfont in Children Under 4 Years With Classic CAH Genetic Condition

MT Newswires Live
·
Jul 02

Neurocrine initiates Phase 2 study of crinecerfont

TIPRANKS
·
Jul 02

Neurocrine Biosciences Announces Press Release Available on Pediatric Crinecerfont Phase 2 CAH Study Initiation

Reuters
·
Jul 02

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

THOMSON REUTERS
·
Jul 02

Neurocrine Biosciences Chief Legal Officer Darin Lippoldt Sells USD 1.91 Million in Common Shares

Reuters
·
Jul 01

Neurocrine Biosciences' Ingrezza Momentum Seen Supporting 2026 Guidance Upgrade, UBS Says

MT Newswires Live
·
Jul 01

Neurocrine (NBIX) Receives a Buy from Jefferies

TIPRANKS
·
Jun 30

Neurocrine price target raised to $208 from $182 at UBS

TIPRANKS
·
Jun 30

Neurocrine Biosciences, Inc : Jefferies Raises Target Price to $200 from $181

THOMSON REUTERS
·
Jun 29